Verona Pharma Announces December 2024 Investor Conference Participation
Verona Pharma (Nasdaq: VRNA) announces its participation in two major healthcare investor conferences in December 2024. The company will present at the Piper Sandler 36th Annual Healthcare Conference in New York on December 3 at 12:00 p.m. ET, and at the 7th Annual Evercore HealthCONx Conference in Miami on December 4 at 3:00 p.m. ET. Webcasts of both presentations will be available on the company's website. Verona Pharma specializes in developing therapies for chronic respiratory diseases, with their first commercial product Ohtuvayre™ (ensifentrine) being a dual-action COPD treatment.
Verona Pharma (Nasdaq: VRNA) annuncia la sua partecipazione a due importanti conferenze per investitori nel settore sanitario a dicembre 2024. L'azienda presenterà al 36° Annual Healthcare Conference di Piper Sandler a New York il 3 dicembre alle 12:00 ET, e al 7° Annual Evercore HealthCONx Conference a Miami il 4 dicembre alle 15:00 ET. I webcast di entrambe le presentazioni saranno disponibili sul sito web dell'azienda. Verona Pharma si specializza nello sviluppo di terapie per malattie respiratorie croniche, con il suo primo prodotto commerciale Ohtuvayre™ (ensifentrine) che è un trattamento a doppia azione per la BPCO.
Verona Pharma (Nasdaq: VRNA) anuncia su participación en dos importantes conferencias de inversores en el sector salud en diciembre de 2024. La compañía presentará en la 36ª Conferencia Anual de Salud de Piper Sandler en Nueva York el 3 de diciembre a las 12:00 p.m. ET, y en la 7ª Conferencia Anual HealthCONx de Evercore en Miami el 4 de diciembre a las 3:00 p.m. ET. Las retransmisiones en vivo de ambas presentaciones estarán disponibles en el sitio web de la empresa. Verona Pharma se especializa en el desarrollo de terapias para enfermedades respiratorias crónicas, siendo su primer producto comercial Ohtuvayre™ (ensifentrina) un tratamiento de acción dual para la EPOC.
베로나 제약 (Nasdaq: VRNA)은 2024년 12월에 열리는 두 개의 주요 헬스케어 투자자 컨퍼런스에 참여한다고 발표했습니다. 회사는 12월 3일 오후 12시(ET)에 뉴욕에서 열리는 파이퍼 샌들러 제36회 연례 헬스케어 컨퍼런스와 12월 4일 오후 3시(ET)에 마이애미에서 열리는 에버코어 제7회 헬스CONx 컨퍼런스에서 발표할 예정입니다. 두 발표의 웹캐스트는 회사 웹사이트에서 제공됩니다. 베로나 제약은 만성 호흡기 질환 치료제를 개발하는 데 전문화되어 있으며, 첫 번째 상업적 제품인 Ohtuvayre™(엔시펜트린)는 이중 작용의 COPD 치료제입니다.
Verona Pharma (Nasdaq: VRNA) annonce sa participation à deux importantes conférences d'investisseurs dans le domaine de la santé en décembre 2024. L'entreprise présentera à la 36e Conférence Annuelle sur la Santé de Piper Sandler à New York le 3 décembre à 12h00 ET, et à la 7e Conférence Annuelle Evercore HealthCONx à Miami le 4 décembre à 15h00 ET. Des webdiffusions des deux présentations seront disponibles sur le site internet de l'entreprise. Verona Pharma se spécialise dans le développement de thérapies pour les maladies respiratoires chroniques, avec son premier produit commercial Ohtuvayre™ (ensifentrine), qui est un traitement à double action contre la BPCO.
Verona Pharma (Nasdaq: VRNA) kündigt seine Teilnahme an zwei wichtigen Gesundheitskonferenzen für Investoren im Dezember 2024 an. Das Unternehmen wird am 3. Dezember um 12:00 Uhr ET auf der 36. jährlichen Gesundheitskonferenz von Piper Sandler in New York und am 4. Dezember um 15:00 Uhr ET auf der 7. jährlichen Evercore HealthCONx-Konferenz in Miami präsentieren. Webcasts beider Präsentationen werden auf der Website des Unternehmens verfügbar sein. Verona Pharma ist auf die Entwicklung von Therapien für chronische Atemwegserkrankungen spezialisiert, wobei das erste kommerzielle Produkt Ohtuvayre™ (Ensifentrin) eine duale COPD-Behandlung ist.
- None.
- None.
LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024:
Piper Sandler 36th Annual Healthcare Conference
Date: Tuesday, December 3, 2024
Time: 12:00 p.m. ET / 5:00 p.m. GMT
Location: New York, NY
7th Annual Evercore HealthCONx Conference
Date: Wednesday, December 4, 2024
Time: 3:00 p.m. ET / 8:00 p.m. GMT
Location: Miami, FL
A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.
For further information please contact:
| Verona Pharma plc | Tel: +1-844-341-9901 |
| Victoria Stewart, Senior Director of Investor Relations and Communications | IR@veronapharma.com |
| Argot Partners (US Investor Enquiries) | Tel: +1-212-600-1902 verona@argotpartners.com |
| Ten Bridge Communications International / US Media Enquiries | Tel: +1-781-316-4424 tbcverona@tenbridgecommunications.com |
| Wendy Ryan |
About Verona Pharma
Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.
FAQ
When is Verona Pharma (VRNA) presenting at the Piper Sandler Healthcare Conference in 2024?
Where can I watch Verona Pharma's (VRNA) December 2024 investor conference presentations?
What conferences is Verona Pharma (VRNA) attending in December 2024?
